Sarah Younger, MD
Internal Medicine · Hampton, VANPI 1881630291
Payments from drug & device makers
Across 280 payments — averaging $40.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$7K
- Novo Nordisk$731
- Lilly USA, LLC$631
- AbbVie$576
- AstraZeneca$476
- Amgen$265
- plus $2K from 33 others
What the payments were for
- Speaking & faculty fees$4,33638%
- Travel & lodging$1,79916%
- Food & beverage$5,15546%
- Education$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 15 | $6,580 |
| Novo Nordisk | 43 | $731 |
| Lilly USA, LLC | 37 | $631 |
| AbbVie | 35 | $576 |
| AstraZeneca | 26 | $476 |
| Amgen | 16 | $265 |
| Pfizer | 16 | $260 |
| Boehringer Ingelheim | 13 | $223 |
| Astellas Pharma US Inc | 8 | $188 |
| Johnson & Johnson | 10 | $186 |
| GSK | 12 | $182 |
| Insightec,inc | 2 | $123 |
| Amarin Pharma, Inc. | 6 | $114 |
| Exact Sciences | 5 | $101 |
| Sanofi-aventis U.S. LLC | 3 | $59 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $51 |
| Novartis | 3 | $51 |
| Merck | 3 | $44 |
| Abbott | 2 | $41 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Corcept Therapeutics | 1 | $34 |
| Inspire Medical Systems, Inc. | 1 | $31 |
| Sanofi Pasteur Inc. | 1 | $29 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Shire North American Group Inc | 2 | $26 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Edwards Lifesciences | 1 | $20 |
| Bausch Health US, LLC | 1 | $19 |
| Antares Pharma, Inc. | 1 | $18 |
| Philips North America LLC | 1 | $17 |
| Cequr Corporation | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Chiesi USA, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Agios Pharmaceuticals, Inc. | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Linus Health, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$6,370
How this compares
$11,318 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 57 | $84,661 |
| JardianceEmpagliflozin | 60 | $68,635 |
| TrulicityDulaglutide | 41 | $55,220 |
| EliquisApixaban | 24 | $31,344 |
| MounjaroTirzepatide | 15 | $24,447 |
| XareltoRivaroxaban | 14 | $23,111 |
| FarxigaDapagliflozin Propanediol | 16 | $22,845 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $22,577 |
| MyrbetriqMirabegron | 25 | $17,499 |
| EntrestoSacubitril/Valsartan | 11 | $15,481 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $11,875 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $8,328 |
| LinzessLinaclotide | 13 | $7,977 |
| Effexor XrVenlafaxine Hcl | 12 | $7,117 |
| Novolog FlexpenInsulin Aspart | 15 | $6,728 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $731 | $84,66157 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $631 | $79,66756 claims |
| Boehringer IngelheimJardiance | $223 | $68,63560 claims |
| PfizerEliquis, Effexor Xr | $260 | $38,46136 claims |
| AstraZenecaFarxiga, Symbicort | $476 | $28,25030 claims |
| Johnson & JohnsonXarelto | $186 | $23,11114 claims |
| Astellas Pharma US IncMyrbetriq | $188 | $17,49925 claims |
| NovartisEntresto | $51 | $15,48111 claims |
| GSKTrelegy Ellipta | $182 | $11,87511 claims |
| AbbVieLinzess, Synthroid | $576 | $8,56135 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $1,604172 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Hampton
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
- Sue BrownCharlottesville$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.